Political courage to boost the life science industry?

2024-01-16T13:08:22+01:00

There is a recognition from the government of the crucial role of the life science sector in the Danish economy, including through the export of pharmaceuticals, and there is a strong appetite to create more growth stories like Novo Nordisk.

Political courage to boost the life science industry?2024-01-16T13:08:22+01:00

Is – or can Denmark become – a leading life science nation?

2024-01-16T12:34:00+01:00

If the pattern of the majority of life science funding in Denmark going to early stages continues, alternative financing options need to be established for more mature companies that require long-term investments to scale up and realize their potential in Denmark.

Is – or can Denmark become – a leading life science nation?2024-01-16T12:34:00+01:00

Disease burdens, clinical studies, and investments – is there proportionality?

2023-11-03T14:55:01+01:00

The reasons for the disparity between the extent of clinical drug research and the disease burden likely vary for different diseases. However, there are probably some common factors, including the ability and willingness to pay or lack thereof, and thus the expected return associated with investment. In these cases, it makes sense to establish commercial incentives for research and development in under-prioritized disease areas.

Disease burdens, clinical studies, and investments – is there proportionality?2023-11-03T14:55:01+01:00

Unnecessary treatments, redundant medicines, or ill-advised decisions?

2023-10-16T12:55:49+02:00

The ongoing discussion about initiatives that can counteract and reduce unnecessary treatments and treatments with low value is also relevant for new medicines. One of the dilemmas here is the weighing of the relationship between the clinical significance of a drug and the costs of treatment with the drug.

Unnecessary treatments, redundant medicines, or ill-advised decisions?2023-10-16T12:55:49+02:00

Will it be possible to use AI for generation of scientific and clinical evidence that is currently demonstrated via traditional randomized controlled trials?

2023-09-13T17:17:43+02:00

There are many questions related to the development, limitations and validity of AI and machine learning applied to healthcare solutions and products. Despite various challenges such as dataset shifts and automation bias, one can envision a future where AI-generated data is used to document clinical safety and efficacy, thereby replacing the randomized controlled trials as we know them today. This would lead to a massive acceleration in the development of new healthcare solutions and products. However, there is still a way to go. Another and perhaps more realistic scenario is broader use of AI-supported clinical research and drug development, where AI and machine learning become an integrated tool for faster and less expensive development of safer and more efficacious healthcare solutions and products. It could be for accurate and comprehensive prediction of desired and unwanted effects, individual disease development, risk profile and prognosis, as well as for identifying which patients will benefit the most from new therapies, and allocation to the optimal treatment offer.

Will it be possible to use AI for generation of scientific and clinical evidence that is currently demonstrated via traditional randomized controlled trials?2023-09-13T17:17:43+02:00
Go to Top